Glenmark Pharmaceuticals Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook

Glenmark Pharmaceuticals (NSE: GLENMARK) is preparing to announce its Q4 FY26 financial results for the period ended March 31, 2026. The board of directors is scheduled to meet on May 2026 (Expected) to approve the audited statements and consider a final dividend recommendation. With Glenmark Pharmaceuticals trading at Rs 1,300 — against a 52-week high of Rs 1,640 and a 1-year return of -12% — the Q4 FY26 results will be a pivotal event for investors.

Analyst estimates for Q4 FY26 revenue stand at Rs 3,850-4,100 Cr, with PAT expectations of Rs 350-400 Cr and margin projections of EBITDA 17-19%. This article covers the Glenmark Pharmaceuticals Q4 results 2026 date, detailed earnings estimates, five key performance factors, five risks to monitor, analyst ratings and price targets, and answers to the most commonly searched investor questions.

Glenmark Pharmaceuticals Q4 Results 2026 Date

Get free investment predictions and live Q4 result alerts on Univest.

Glenmark Pharmaceuticals has scheduled its Q4 FY26 results for May 2026 (Expected). Here is the broader Q4 FY26 earnings calendar context:

Why This Quarter Matters

Glenmark Pharmaceuticals enters Q4 FY26 with expectations of 10-14% YoY revenue growth. Q4 is the final quarter of the financial year — it determines full-year FY26 performance, sets the FY27 estimate base, and triggers final dividend announcements. At a 1-year return of -12%, this quarter’s results and FY27 guidance will be critical in determining whether the stock can begin a recovery.

Glenmark Pharmaceuticals Q4 FY26 Earnings Estimates

Access premium SEBI-registered research on Univest.

Beyond headline numbers, investors will watch for FY27 guidance, margin trajectory, and order/deal pipeline updates. A positive surprise on any two of these parameters could drive a meaningful post-results re-rating.

Screen Glenmark Pharmaceuticals fundamentals on Univest Screener.

5 Key Factors That Will Drive Glenmark Pharmaceuticals Q4 FY26 Performance

Revenue Momentum

Analysts expect Rs 3,850-4,100 Cr in revenue for Q4 FY26 (Q3: Rs 3,684 Cr). Management’s ability to translate the order pipeline into recognised revenue will be the first test. Q4 is seasonally important for the Pharma sector, driven by year-end order execution and government capex push.

Margin Trajectory

Q4 FY26 margin expectations are EBITDA 17-19%, compared to EBITDA 16.8% in Q3. Input cost trends, employee expenses, and pricing power will determine the outcome. Any margin beat would be a significant positive catalyst given sector-wide cost pressure.

PAT Quality

Net profit is estimated at Rs 350-400 Cr. Investors will assess whether PAT is driven by operational improvement or one-time items. A clean recurring profit print is more positively received than one inflated by non-operational gains.

Management Guidance for FY27

The most consequential output from the Q4 FY26 announcement will be FY27 guidance — revenue growth bands, margin targets, capex plans, and macro risk commentary. Credible and specific guidance for FY27 will be valued highly by institutional investors.

Dividend Declaration

Glenmark Pharmaceuticals is expected to consider a final dividend of Rs 5-8 per share at the board meeting. The quantum signals confidence in free cash flow generation and sets expectations for FY27 capital allocation strategy.

5 Risks to Watch in Glenmark Pharmaceuticals Q4 FY26

US Tariff and Macro Headwinds

The 26% US reciprocal tariff on Indian goods has created macro uncertainty affecting all Indian equities. For Glenmark Pharmaceuticals, indirect impacts include FII outflows and earnings estimate cuts if global demand slows. Tariff negotiation progress between India and the US remains the key macro wildcard.

Earnings Miss Risk

If Glenmark Pharmaceuticals’s Q4 FY26 results miss estimates, the stock could correct sharply — regardless of the longer-term fundamental story. Investors should monitor revenue versus the Rs 3,850-4,100 Cr estimate and PAT versus Rs 350-400 Cr as the two primary watchpoints on results day.

FY27 Guidance Below Consensus

If management’s FY27 guidance for revenue or margins falls below Street expectations, the stock may decline even if Q4 numbers are in line. In the current macro environment, forward guidance carries more weight than the reported quarter.

FII Outflow Continuation

FIIs sold Rs 22,000 crore in Indian equities in one week following the tariff announcement. Continued selling pressure would create headwinds for Glenmark Pharmaceuticals regardless of company-specific fundamentals.

Regulatory Risk

The Pharma sector operates within evolving regulatory frameworks. Any policy changes that increase compliance costs or alter competitive dynamics could affect Glenmark Pharmaceuticals’s profitability beyond current consensus models.

Glenmark Pharmaceuticals Share Price and Analyst Ratings

Glenmark Pharmaceuticals share price snapshot and analyst ratings. Source: Brokerages, NSE data.

Glenmark Pharmaceuticals is trading at Rs 1,300 as of early April 2026, against a 52-week high of Rs 1,640 and 52-week low of Rs 1,050. Market cap stands at Rs 36,800 Cr. The 1-year return of -12% reflects sector headwinds alongside company-specific factors.

Download the Univest iOS App or Univest Android App to track Glenmark Pharmaceuticals’s live price and receive real-time Q4 result alerts.

Conclusion

Glenmark Pharmaceuticals Q4 FY26 results on May 2026 (Expected) will be a key event for investors monitoring the Pharma sector. Analysts project PAT of Rs 350-400 Cr and revenue of Rs 3,850-4,100 Cr. At a CMP of Rs 1,300 with analyst targets ranging from Rs 1,480 to Rs 1,400, the stock offers risk-reward for informed investors. FY27 guidance will be the most critical post-results catalyst.

For more Q4 FY26 previews across sectors, visit Univest Blogs.

Frequently Asked Questions

What is the Glenmark Pharmaceuticals Q4 results 2026 date?

The Glenmark Pharmaceuticals Q4 results 2026 date is May 2026 (Expected). The board of directors will meet to approve the audited Q4 FY26 financial results and consider a dividend recommendation for FY26.

What is the Glenmark Pharmaceuticals Q4 FY26 PAT estimate?

Analysts estimate Glenmark Pharmaceuticals Q4 FY26 PAT in the range of Rs 350-400 Cr, based on revenue of Rs 3,850-4,100 Cr and margin of EBITDA 17-19%. Actual results may differ from consensus estimates.

What is Glenmark Pharmaceuticals’s share price ahead of Q4 results?

Glenmark Pharmaceuticals is trading at Rs 1,300 as of early April 2026. The 52-week high is Rs 1,640 and the 52-week low is Rs 1,050. The 1-year return is -12% and market cap is Rs 36,800 Cr.

Will Glenmark Pharmaceuticals declare a dividend in Q4 FY26?

Glenmark Pharmaceuticals is expected to consider a final dividend of Rs 5-8 per share at the Q4 FY26 board meeting on May 2026 (Expected), subject to board approval and AGM ratification.

Which analysts have a Buy rating on Glenmark Pharmaceuticals?

YES Securities (Buy, Rs 1,500), JM Financial (Add, Rs 1,420), Emkay (Buy, Rs 1,480) have positive ratings on Glenmark Pharmaceuticals heading into Q4 FY26.

What were Glenmark Pharmaceuticals Q3 FY26 results?

Glenmark Pharmaceuticals reported Q3 FY26 revenue of Rs 3,684 Cr and PAT of Rs 320 Cr, with margin at EBITDA 16.8%. These form the baseline against which Q4 FY26 estimates are benchmarked.

When do Infosys and TCS announce Q4 results 2026?

TCS declared Q4 FY26 results on April 9, 2026. Read the TCS Q4 Results 2026 preview on Univest Blogs. Infosys Q4 FY26 results are scheduled for April 23, 2026. Read the Infosys Q4 Results 2026 preview on Univest Blogs.

Is Glenmark Pharmaceuticals a good investment ahead of Q4 results?

This depends on your risk appetite, investment horizon, and portfolio context. Glenmark Pharmaceuticals has compelling long-term factors alongside genuine near-term risks. Consult a SEBI-registered financial advisor before making any investment decision. Use the Univest Screener to assess fundamentals independently.

Disclaimer: Investment in the share market is subject to risk. This article is for informational and educational purposes only and does not constitute investment advice. All financial data and analyst estimates are sourced from publicly available information including NSE/BSE filings. Verify all numbers before investing. Consult a SEBI-registered advisor before making investment decisions.

Recent Article

Indian Oil Corporation Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook

Gujarat Gas Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook

Indus Towers Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook

Adani Total Gas Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook

Adani Enterprises Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook